Boron vs Tamoxifen for hormones
Short answer: For hormones, more users report improvement with Tamoxifen — 98% of 49 reports, versus 88% of 77 for Boron.
Boron has 38 meta-analyses and 39 randomized trials on PubMed; Tamoxifen has 479 and 1,597.
Based on 459 reports about Boron and 298 about Tamoxifen. Not medical advice.
| Boron Supplement | Tamoxifen Medication | |
|---|---|---|
| Users say it helped | 68%helped129 reports · high confidence | 64%helped75 reports · medium confidence |
| Verdict | Mostly positive | Mostly positive |
| Research | AResearch: Strong | AResearch: Strong |
| Meta-analyses / RCTs | 38 / 39 | 479 / 1,597 |
| Mainly used for | ||
| Hormones % reporting improvement | 88% (77) | 98% (49) |
| Libido % reporting improvement | 88% (52) | 57% (7) |
| Mood % reporting improvement | 71% (14) | 0% (2) |
| Energy % reporting improvement | 88% (8) | 100% (5) |
| Performance % reporting improvement | 75% (8) | 50% (2) |
| Common side effects | irritability, joint pain, fatigue, depression | fatigue, depression, low libido, headache |
| Typical dose reported | 10 mg / daily | Not listed |
Regardless, some MTEs may possess the potential to improve athletic performance, but more high quality research is required before support for these MTEs can be given. PROSPERO preregistered (CRD42018090502).
Nutrients, 2019 ↗“No one has mentioned Boron and Zinc. They make a very noticeable difference for me.”
5 years of adjuvant tamoxifen safely reduces 15-year risks of breast cancer recurrence and death. ER status was the only recorded factor importantly predictive of the proportional reductions. Hence, the absolute risk reductions produced by tamoxifen depend on the absolute breast cancer risks (after any chemotherapy) without tamoxifen.
Lancet, 2011 ↗“This is now 2nd day on nolva and I swaer my balls are about back to normal. Energy is a bit better”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate